Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8.

Wu T, Wang Z, Liu Y, Mei Z, Wang G, Liang Z, Cui A, Hu X, Cui L, Yang Y, Liu CY.

Clin Immunol. 2014 Oct;154(2):116-26. doi: 10.1016/j.clim.2014.07.005. Epub 2014 Jul 23.

PMID:
25063444
2.

The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.

Ying J, Tsujii M, Kondo J, Hayashi Y, Kato M, Akasaka T, Inoue T, Shiraishi E, Inoue T, Hiyama S, Tsujii Y, Maekawa A, Kawai S, Fujinaga T, Araki M, Shinzaki S, Watabe K, Nishida T, Iijima H, Takehara T.

Int J Oncol. 2015 Apr;46(4):1551-9. doi: 10.3892/ijo.2015.2851. Epub 2015 Jan 26.

PMID:
25625841
3.

Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.

Han Y, Cai H, Ma L, Ding Y, Tan X, Liu Y, Su T, Yu Y, Chang W, Zhang H, Fu C, Cao G.

Eur J Cancer. 2013 Nov;49(16):3420-30. doi: 10.1016/j.ejca.2013.06.001. Epub 2013 Jun 25.

PMID:
23809767
4.

RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients.

Cross-Knorr S, Lu S, Perez K, Guevara S, Brilliant K, Pisano C, Quesenberry PJ, Resnick MB, Chatterjee D.

BMC Cancer. 2013 Oct 8;13:463. doi: 10.1186/1471-2407-13-463.

5.

Oct4-related cytokine effects regulate tumorigenic properties of colorectal cancer cells.

Chang CJ, Chien Y, Lu KH, Chang SC, Chou YC, Huang CS, Chang CH, Chen KH, Chang YL, Tseng LM, Song WS, Wang JJ, Lin JK, Huang PI, Lan YT.

Biochem Biophys Res Commun. 2011 Nov 18;415(2):245-51. doi: 10.1016/j.bbrc.2011.10.024. Epub 2011 Oct 19.

PMID:
22037460
6.

Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.

Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN.

Ann Surg. 2012 Oct;256(4):642-50. doi: 10.1097/SLA.0b013e31826b4dcc.

7.

Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.

Zhang W, Stoehlmacher J, Park DJ, Yang D, Borchard E, Gil J, Tsao-Wei DD, Yun J, Gordon M, Press OA, Rhodes K, Groshen S, Lenz HJ.

Clin Colorectal Cancer. 2005 Jul;5(2):124-31.

PMID:
16098254
8.

Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.

Adamo V, Franchina T, Minciullo PL, Pace E, Colonese F, Ricciardi GR, Saitta S, Ferraro M, Spatari G, Gangemi S.

J Cell Physiol. 2011 Nov;226(11):3032-4. doi: 10.1002/jcp.22653.

PMID:
21302302
9.

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.

Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.

Cancer Chemother Pharmacol. 2011 Aug;68(2):317-23. doi: 10.1007/s00280-010-1496-5. Epub 2010 Oct 24.

PMID:
20972872
10.

Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner.

Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z, Qian W.

Biochem Biophys Res Commun. 2015 Feb 20;457(4):681-7. doi: 10.1016/j.bbrc.2015.01.048. Epub 2015 Jan 21.

PMID:
25617735
11.

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL.

Mol Oncol. 2013 Jun;7(3):637-46. doi: 10.1016/j.molonc.2013.02.016. Epub 2013 Feb 28.

12.

Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.

Xu J, Mo Y, Wang X, Liu J, Zhang X, Wang J, Hu L, Yang C, Chen L, Wang Y.

J Gastroenterol. 2013 Feb;48(2):203-13. doi: 10.1007/s00535-012-0623-y. Epub 2012 Jul 21.

PMID:
22820863
13.

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.

Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo G, André T, Mabro M, Mineur L, Flesch M, Carola E, de Gramont A.

Br J Clin Pharmacol. 2010 Jan;69(1):58-66. doi: 10.1111/j.1365-2125.2009.03556.x.

14.

Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma.

Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y.

Clin Cancer Res. 2012 Sep 15;18(18):5144-53. doi: 10.1158/1078-0432.CCR-12-0701. Epub 2012 Jul 30.

15.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
16.

Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.

Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, Wang X, Ji T, Wang S, Ma D, Chen G, Gao Q.

Biochem Biophys Res Commun. 2013 May 31;435(2):188-94. doi: 10.1016/j.bbrc.2013.04.087. Epub 2013 May 7.

PMID:
23665025
17.

The evolving role of oxaliplatin in the management of colorectal cancer.

de Gramont A, Schmoll HJ, Cervantes A, Tournigand C.

Colorectal Dis. 2003 Nov;5 Suppl 3:10-9. Review.

PMID:
23573556
18.

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.

Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P.

J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004.

PMID:
24316553
19.

[FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].

Nozawa H, Kitayama J, Sunami E, Saito S, Kanazawa T, Kazama S, Yazawa K, Kawai K, Mori K, Nagawa H.

Gan To Kagaku Ryoho. 2011 Oct;38(10):1627-32. Japanese.

PMID:
21996957
20.

How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?

Suenaga M, Matsusaka S, Watanabe T, Kuboki Y, Shinozaki E, Chin K, Mizunuma N, Ueno M, Yamaguchi T, Hatake K.

Asia Pac J Clin Oncol. 2011 Jun;7(2):129-35. doi: 10.1111/j.1743-7563.2011.01385.x.

PMID:
21585692

Supplemental Content

Support Center